ALKS
Alkermes plc
25.91
USD
This page is just a preview of the data found in TrendSpider’s full version
Alkermes plc stock is up 5.71% since 30 days ago. The next earnings date is Feb 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 76.67% of the previous 29 December’s closed higher than November. In the last 9 Unusual Options Trades, there were 7 PUTs, 2 CALLs. 0% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 16 Oct 17:23 | 17 Nov, 2023 | 27.00 | 28 | ||
| 18 Oct 16:27 | 19 Jan, 2024 | 29.00 | 16 | ||
| 18 Oct 16:30 | 19 Jan, 2024 | 29.00 | 16 | ||
| 23 Oct 14:16 | 17 Nov, 2023 | 35.00 | 0 | ||
| 23 Oct 14:24 | 17 Nov, 2023 | 26.00 | 305 | ||
| 25 Oct 13:35 | 17 Nov, 2023 | 27.00 | 235 | ||
| 25 Oct 14:04 | 19 Jan, 2024 | 22.00 | 0 | ||
| 03 Nov 15:11 | 17 Nov, 2023 | 28.00 | 1102 | ||
| 06 Nov 15:14 | 17 May, 2024 | 30.00 | 0 |
Alkermes plc researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL, and VUMERITY. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate.
